Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.
BACKGROUND
The role of chemotherapy for neuroendocrine tumours remains controversial and there is no standard regimen.


METHODS
We report the outcome for a consecutive series of chemonaive patients with metastatic or locally advanced neuroendocrine tumours treated with a combination of 5-fluorouracil (500 mg m(-2)), cisplatin (70 mg m(-2)) and streptozocin (1000 mg m(-2)) (FCiSt) administered three weekly for up to six cycles. Patients were assessed for radiological response, toxicity and survival.


RESULTS
In the 79 patients assessable for response, treatment with FCiSt was associated with an overall response rate of 33% (38% for pancreatic primary sites and 25% for non-pancreatic primary sites). Stable disease occurred in a further 51%, with progression in 16%. The median time to progression was 9.1 months and median overall survival was 31.5 months. The most common grade 3-4 toxicity was neutropaenia (28% patients) but grade 3-4 infection was rare (7%). The most frequent non-haematological grade 3-4 toxicity was nausea and vomiting (17%). Prognostic factors included Ki-67, mitotic index, grade and chromogranin A, whereas response to chemotherapy was predicted by mitotic index, grade and alpha-fetoprotein.


CONCLUSIONS
FCiSt is an effective regimen for neuroendocrine tumours with an acceptable toxicity profile. Grade and mitotic index are the best predictors of response.
Department of Oncology, UCL Medical School, Royal Free Campus, London, UK.
N C
NC
Turner
S J
SJ
Strauss
D
D
Sarker
R
R
Gillmore
A
A
Kirkwood
A
A
Hackshaw
A
A
Papadopoulou
J
J
Bell
I
I
Kayani
C
C
Toumpanakis
F
F
Grillo
A
A
Mayer
D
D
Hochhauser
R H
RH
Begent
M E
ME
Caplin
T
T
Meyer
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000401:mortality; D013311:Streptozocin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
D013311:Streptozocin; D002945:Cisplatin; D005472:Fluorouracil